Four injections a year! FDA Approves invega trinza, the world's first 3-month long-acting schizophrenia drug

Source: Biovalley 2015-05-22 May 22, 2015 news: Recently, the new drug regulatory of Johnson & Johnson (JNJ) has gained a lot of news The long-term atypical antipsychotic drug invega trinza (sustained-release injection of paparenone palmitate, intramuscular injection every 3 months) developed by the company has been approved by the FDA of the United States The drug is approved every 3 months Once a month, only four times a year, for the treatment of adults with schizophrenia Approved by the FDA's priority review process, invega trinza is the world's first and only schizophrenic drug to be used only four times a year Johnson & Johnson has planned to bring invega trinza to market in mid June In a phase III clinical trial of long-term maintenance therapy, up to 93% of patients in the investga trinza treatment group did not experience significant relapse of schizophrenia symptoms, and the study was terminated early after review by the independent data monitoring committee (IDMC) Relevant data have been published in the Journal of JAMA psychiatry According to FDA information, schizophrenics must receive at least 4 months of full treatment with the long-acting atypical antipsychotic drug invega sustenna (paparenone palmitate slow release injection, intramuscular injection once a month) before starting treatment with invega trinza In 2011 and 2014, invega sustenna was approved by the FDA for the treatment of schizophrenia and bipolar disorder The sales volume of the drug in 2014 was up to US $1.5 billion, while the sales volume of short-term version invega in 2014 was US $640 million Previously, decision resources, a pharmaceutical market research institution, released a report, predicting that the global market for schizophrenia treatment will reach US $6.4 billion in 2017 However, invega trinza, a long-term new drug injected only four times a year by Johnson & Johnson, will become one of the main drivers of market growth, and will bring heavy returns to Johnson & Johnson at the same time However, the report points out that Johnson & Johnson still faces many challenges in the market of long-acting antipsychotic drugs On the one hand, the Danish pharmaceutical giants lundbeck and Otsuka are vigorously marketing their monthly long-acting schizophrenia drug, abilify maintena, which is expected to have a peak sales of $500-1 billion On the other hand, Eli Lilly, an American pharmaceutical giant, is also actively marketing another long-acting version of schizophrenia drug Zyprexa relprevv (olanzapine dihydroxynaphthenate long-acting injection, once a month), which is the successor of Zyprexa, a blockbuster schizophrenia drug once sold by Lilly After the expiration of Zyprexa patent, the launch of Zyprexa relprevv, a long-term drug, has greatly helped Lilly maintain its brand operation.